Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

摘要: Overexpression of the HER2/neu oncogene and receptor protein has been reported in 20%-30% patients with breast cancer is associated a poor prognosis. expression assessed by fluorescence situ hybridization or immunohistochemistry predictor for response to trastuzumab, humanized monoclonal antibody against cell-surface protein. Data regarding lung are more limited, there little information trastuzumab alone combination chemotherapeutic agents. Gemcitabine an active agent non-small-cell (NSCLC) demonstrated activity as well. In vitro modified tetrazolium salt growth assays were performed determine whether trastuzumab/gemcitabine produced synergistic additive effects on cell lines. The alone, gemcitabine was evaluated 4 NSCLC lines, 1 small-cell (SCLC) line, 2 surface flow cytometry immunohistochemistry. Fluorescence analysis used study gene expression. Trastuzumab treatment resulted inhibition all lines expressing inhibitive effect correlated level Treatment both A seen trastuzumab/ indicated index values < 1. degree synergy observed did not directly correlate expression, even low levels HER2/neu. No SCLC which express These preclinical studies indicate need clinical gemcitabine/trastuzumab whose tumors overexpress HER2/ neu.